

## DAFTAR PUSTAKA

- Al-Ahwal, M.S. 2005. Pattern of febrile neutropenia in solid tumors - A hospital based study. *Pakistan Journal of Medical Sciences*, 2005; 21, 249-252.
- Alves-Filho, J.C., Spiller, F., Cunha, F.Q. 2010. Neutrophil paralysis in sepsis. *Shock*; 34 Suppl 1:15
- Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med*; 29:1303–1310
- Bassam, H., Zuraidah, M.Y., Saad, B.O. 2009. Neutropenia onset, severity and their association with demographic data. *Asian Journal of Pharmaceutical and Clinical Research*, 2, 51-53.
- Blouin, A., Pastores, S., Halpern, N., Fleisher, M., Ramanathan, L. 2017. Procalcitonin and Cytokine Levels in Cancer Patients with Neutropenia and Blood Stream Infections. *Critical Care Medicine* Vol 46, Number 1 (Supplement)
- Bolyard, A.A., Edwards, C., Kinsey, S., Schwinzer, B., Zeidler, C. 1994. Understanding severe chronic neutropenia, *Oaks, CA, USA*, Scnir.
- Brown, K.A., Brain, S.D., Pearson, J.D., Edgeworth, J.D, Lewis, S.M., Treacher, D.F. 2006. Neutrophils in development of multiple organ failure in sepsis. *Lancet*; 368(9530):157–69.
- Buffoni, L., Dongiovanni, D., Barone, C., Fissore, C., Ottaviani, D., Dongiovanni, V., Grillo, R., Salvadori, A., Birocco, N., Schena, M., Bertetto, O. 2006. Fractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: phase II trial. *Lung Cancer*; 54, 353-357.
- Chaftari, A.M., Hachem, R., Reitzel, R., Jordan, M., Jiang, Y., Yousif, A., Garoge, K., Deshmukh, P., Al Hamal, A., Jabbour, J., Hanania, A., Raad, S., Jamal, M., Raad, I. 2015. Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. *PLOS ONE*.
- Crawford, J. 2007. Update on neutropenia and myeloid growth factors. *Supportive Oncology*; 5(4): 27-29.
- Dale, D.C. 2005. Neutropenia. In: Herman NW. (ed.) *Encyclopedia of Life Sciences*. Chichester John Wiley & Son's, Ltd; p10 - 32.
- Danai, P.A., Moss, M., Mannino, D.M., et al. 2006. The epidemiology of sepsis in patients with malignancy. *Chest*; 129:1432–1440.
- Dellinger, P., Levy, M.M. Carlet, J.M., Bion, J.B., Parker, M.M., Jaeschke, R., Reinhart, K., Angus, D.C, Brun-Buisson, C., Beale, R., Calandra, T.,

- Dhainaut, J.F., Gerlach, H., Harvey, M.R.N., Marini, J.J., Marshall, J., Ranieri, M., Ramsay, G., Sevransky, J., Thompson, B.T., Townsend, S., Vender, J.S., Zimmerman, J.L., Vincent, J.L. 2013. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: International Surviving Sepsis Campaign Guidelines Committee
- De Prost, N., Razazi K., Brun-Buisson, C. 2013. Unrevealing culture-negative severe sepsis. *Critical Care*, 17:100
- Djitmau, A.S.L. 2016. Perbedaan sensitivitas dan spesifisitas DNI dan prokalsitonin dalam menegakkan diagnosis sepsis. Tesis. Fakultas Kedokteran UGM. Yogyakarta.
- Durnaś, B., Wątek, M., Wollny, T., Niemirowicz, K., Marzec, M., Bucki, R., Gózdź, S. 2016. Utility of blood procalcitonin concentration in the management of cancer patients with infections. *OncoTargets and Therapy*; 9 469–475
- Fortner, B.V., Schwartzberg, L., Tauer, K., Houts, A.C., Hackett, J., Stolshek, B.S. 2005. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. *Support Care Cancer*; 13, 522-528.
- Frey, R., Granger, J. 2002. Neutropenia. In: Thackery E. (ed) The gale encyclopedia of cancer, Detroit: Gale Group; p. 770-773.
- Furze, R.C., Rankin, S.M. 2008. Neutrophil mobilization and clearance in the bone marrow. *Immunology*; 125:281 8.
- Gaieski, D.F., Edwards, J.M., Kallan, M.J, Carr, B.G. 2013. Benchmarking the incidence and mortality of severe sepsis in the United States. *Crit Care Med.*; 41(5):1167–74.
- Hassan, B.A.R., Zuraidah, M.Y., Saad, O. 2011. Association of neutropenia onset and severity with chemotherapy regimens and schedules. *Asian Pacific Journal of Cancer Prevention*; 12, 1425-1428.
- Hazeldine, J., Hampson, P., Lord, J.M. 2014. The impact of trauma on neutrophil function. *Injury*; 45:1824-33. doi: 10.1016/j.injury.2014.06.021.
- Hermawan, A.G. 2014. Sepsis dalam Buku Ajar Ilmu Penyakit Dalam Jilid I edisi VI. Interna Publishing. Jakarta.
- Jemal, A., Center, M.M., DeSantis, C., Ward, EM. 2010. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev*, 19, 1893-907
- Kim, E., Schueller, O., Sweetnam, P.M. 2012. Targeting the leukocyte activation cascade: Getting to the site of inflammation using microfabricated assays. *Lab Chip* 2012;12: 2255-64.

- Kimble-Koda, M.A., Young, L.Y., Kardjan, W.A., Guglielmo, B.J. 2002. Infections in Neutropenic Patients. In: Troy D. (eds.) *Hand Book of Applied Therapeutics*, Philadelphia, Lippincott Williams & Wilkins; 2002. p203-241.
- Koasak, Ü., Rolston, K.V.I., Mullen, C.A. 2002. Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia. *Support Care Cancer*, 2002; 10: 58-64.
- Kolaczowska, E., Kubes, P. 2013. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol*; 13:15975.
- Lakshmikanth, C.L., Jacob, S.P., Chaithra, V.H., de Castro-Faria-Neto, H.C., Marathe, GK. 2016. Sepsis: in search of cure. *Inflamm Res*, [Epub ahead of print]
- Leli, C., Ferranti, M., Moretti, A., Al Dhahab, Z.S., Cenci, E., Mencacci, A. Procalcitonin Levels in Gram-Positive, Gram-Negative, and Fungal Bloodstream Infections. *Hindawi Publishing Corporation Disease Markers*. Volume 2015, Article ID 701480,8 pages
- Levy, M.M., Fink, M.P., Marshall, J.C., et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 31:1250–1256
- Lever A, Mackenzie I. 2007. Sepsis: definition, epidemiology and diagnosis. *BMJ*,335:879-883.
- Liu, H.H, Guo, J.B., Geng, Y., Su, L. 2015. Procalcitonin: present and future. *Ir J Med Sci*;184 (3):597–605
- Lyman, G.H., Wilmot, J.P. 2006. Risks and consequences of chemotherapy-induced neutropenia. *Clinical Cornerstone*; 8, 12-18.
- Martin, G.S., Mannino, D.M., Eaton, S., Moss, M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*, 348, 1546-54
- Muller, B., White, J. C. Nylen, J. C. Snider, R. H. Becker, K. L. and Habener, J. F. 2001. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis,"*The Journal of Clinical Endocrinology & Metabolism*, vol. 86, no. 1, pp. 396–404,
- National Cancer Registry of Malaysia. 2003. Second Report of the National Cancer Registry Cancer Incidence in Malaysia. In: Malaysia MOH (ed.) *National Cancer Registry*; p. 1-141.
- Nasa, P., Juneja, D., Singh, O. 2012. Severe sepsis and septic shock in the elderly: An overview. *World J Crit Care Med*. February 4; 1(1): 23-30

- Opal, S.M, Laterre, P.F., Francois, B., La-Rosa, S.P., Angus, D.C., Mira, J.P, et al. 2013. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. *JAMA*; 309(11):1154–62.
- Pereira, F.M., Alves, S., Dias, J., Guerreiro, I.M., Silva, M.J., Afonso, A., Mergulhão, P., Savva-Bordalo, J., Pereira, D. 2016. Impact of sepsis and organ dysfunction on cancer patients Mortality. *Annals of Oncology*: vi497–vi521, doi:10.1093/annonc/mdw390.22
- Phua, J., Ngerng, W.J., See, K.C., Tay, C.K., et al. 2013. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Critical Care*,17: R202
- Poltorak, A., He, X., Smirnova, I., et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4gene. *Science*. vol. 282, no. 5396, pp. 2085–2088.
- Rankin, SM. 2010. The bone marrow: A site of neutrophil clearance. *J Leukoc Biol*; 88:241-251.
- Reilly, J.P., Anderson, B.J., Hudock, K.M., Dunn, T.G., Kazi, A.,Tommasini, A., Charles, D., Shashaty, M.G.S., Mikkelsen, M.E., Christie, J.D., Meyer, N.J. 2016. Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis. *Critical Care* 20:222
- Remick, D.G. 2004. Do not get sick when you are sick: the impact of comorbid conditions. *Crit Care Med*; 32:2147–2148.
- Riedel, S., Melendez, J.H., Janet, A.T., Zenilman, J.M. 2011. Procalcitonin as a Marker for the Detection of Bacteremia and Sepsis in the Emergency Department. *American Journal of Clinical Pathology* 2011;135:182-189.
- Rolston, K.V.I. 2001. Infections in Patients with Solid Tumors. In: Rolston KVI., Rubenstein EB. (eds.) *Text Book of Febrile Neutropenia*. London: Martin Dunitz Ltd; p. 91-109.
- Sadik, C.D., Kim, N.D., Luster, A.D. 2011. Neutrophils cascading their way to inflammation. *Trends Immunol*; 32:452-60.
- Safdar, A., Armstrong, D. 2001. Infectious morbidity in critically ill patients with cancer. *Crit Care Clin*; 17:531–570.
- Schuetz, P., Albrich, W., Mueller, B. 2011. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Medicine* 2011, 9:107.
- Sharma A., Lokeshwar N. 2005. Febrile neutropenia in haematological malignancies. *Journal of Postgraduate Medicine*; 51, 42-48.

- Silva, E., Cavalcanti A.B., Bugano, D.D., Janes, J.M., Vallet, B., Beale, R., et al. 2012. Do established prognostic factors explain the different mortality rates in ICU septic patients around the world? *Minerva Anestesiol*; 78(11):1215–25.
- Takeuchi, O., Hoshino, K., Kawai, T., et al. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram positive bacterial cell wall components. *Immunity*, vol.11 no. 4, pp. 443–451.
- Tang, B.M.P., Eslick, G.D., Craig, J.C., McLean, A.S., 2007. Accuracy of Procalcitonin for Sepsis Diagnosis in Critically Ill Patients: Systematic Review and Meta-analysis. *Lancet Infect Dis* 2007; 7:210–17
- Tolsma, V., Schwebel, C., Azoulay, E., Darmon, M., Souweine, B., Vesin, A., et al. 2014. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. *Chest*; 146(5):1205–13.
- Vänskä, M. 2015. Biomarkers of Sepsis in Neutropenic Hematological Patients. Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 279.
- Verstraete, M., Vrhaghe, R., Peerlinck, K., Boogaerts, M.A. 1997. Haematological Disorders. In: Speight T.M., Holford NH. (eds.) A very's Drug Treatment. Auckland, Adis Press. p 56-68.
- Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., et al. 2009. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*; 302(21):2323–9.
- Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., et al. 2009. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*; 302(21):2323–9.
- Voelker, M.D., Rubenstein, L.M., Chrischilles, E.A., Chen-Hardee, S.S., Link, B.K., Wright, K.B., Brooks, J.M., Delgado, D.J. 2004. Time to first neutropenia hospitalization during firstcourse chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: national SEER-medicare study. *Journal of Supportive Oncology*; 2: 40-41.
- Williams, M.R., Azcutia, V., Newton, G., Alcaide, P., Luscinskas, F.W. 2011. Emerging mechanisms of neutrophil recruitment across endothelium. *Trends Immunol*; 32:461-9
- Williams, M.D., Braun, L.A., Cooper, L.M., Johnston, J., Weiss, R.V., Qualy, R.L., Linde-Zwirble, W. 2004. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. *Crit Care*; 8:R291–R298.

- Wolff, D., Crawford, J., Dale, C.D., Poniewierski, M.S., Lyman, G.H. 2005. Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systemic chemotherapy. *Journal of Support Oncology*, 3, 56-57.
- Wolff, D., Culakova, E., Poniewierski M.S., Lyman, G.H., Dale, D.C. & Crawford, J. Predictors of chemotherapy-induced neutropenia and Its complications: results from a prospective nationwide registry. *Journal of Supportive Oncology*, 2005; 3, 24-25.
- Yan, S.T., Sun, L.C., Jia, H.B., Gao, W., Yang, J.P., Zhang, G.Q. 2017. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. *American Journal of Emergency Medicine*. 35; 579-583
- Yang, Y., Yang, K.S., Hsann, Y.M., Lim, V., Ong, B.C. 2010. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis. *J Crit Care*; 25: 398-405
- Yip, C., Kasule, OH. 2005. Epidemiology of breast cancer in Malaysia. *International Medical Journal*; 4, 1.
- Zhou, J., Qian, C., Zhao, M., *et al.* 2014. Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland China. *PLoS One*, 9, 107181